{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"EP_2256214_A1","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"017-979-765-787-382","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10766,"type":"PATENT","title":"Heidelberg University - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":2033,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8238,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:\"Univ* heide*\"; \"Univ Ruprecht Karls\".
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1714
Search Applicants and Owners separately:\"Univ* heide*\"; \"Univ Ruprecht Karls\".
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1714
(a) obtaining a brain tumor sample from a patient; and
(b) determining the presence of a mutation at position 132 of isocitrate dehydrogenase (IDH1) on the protein level using an antibody that can distinguish between an IDH1 protein harbouring said mutation and an unmutated version of the protein; whereby a patient harbouring said mutation has a better prognosis than a patient without said mutation."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["A method of selecting a therapy modality for a patient afflicted with a brain tumor, comprising
(a) obtaining a brain tumor sample from said patient; and
(b) determining the presence of a mutation at position 132 of isocitrate dehydrogenase (IDH1) on the protein level using an antibody that can distinguish between an IDH1 protein harbouring said mutation and an unmutated version of the protein; whereby the selection of a therapy modality depends on the presence or absence of said mutation."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["A method of diagnosing a brain tumor in a patient suspected of having a brain tumor, comprising
(a) obtaining a brain sample suspected of harboring a tumor from said patient; and
(b) determining the presence of single tumor cells within otherwise inconspicuous tissue by using an antibody that specifically binds to an isocitrate dehydrogenase (IDH1) protein harbouring a mutation at position 132."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, 2 or 3, wherein said mutation is R132H."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of any one of claims 1 to 4, wherein said brain tumor is a glioma."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 5, wherein said glioma is fibrillary astrocytoma WHO grade II, oligoastrocytoma WHO grade II, oligodendroglioma grade II, anaplastic astrocytoma WHO grade III, anaplastic oligoastrocytoma WHO grade III, anaplastic oligodendroglioma grade III or glioblastoma."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 3 wherein the tumor is a low grade astrocytoma or an oligodendroglioma."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of any one of claims 1 to 7, wherein said antibody is raised using the peptide CKPIIIGHHAYGD as an immunogen."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of any one of claims 2, 4, 5, 6 or 8, wherein said therapy modality (a) acts on cell proliferation, cell survival and/or cell motility, and/or (b) comprises administration of a chemotherapeutic agent."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 10, wherein the therapy (a) and/or (b) acts on angioneogenesis."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9 or 10, wherein said therapy modality comprises chemotherapy, administration of a small molecule inhibitor, antibody based regimen, anti-proliferation regimen, pro-apoptotic regimen, pro-differentiation regimen, radiation and/or surgical therapy."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method of any of claims 1-11, wherein the antibody is generated by a hybridoma deposited with the DSMZ and having accession number DSM ACC3009."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["Antibody generated by a hybridoma deposited with the DSMZ and having accession number DSM ACC3009."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["A kit useful for carrying out a method of any one of claims 1 to 12, comprising an antibody that specifically binds to an IDH1 protein harbouring said mutation."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The kit of claim 14 wherein said antibody is the antibody as defined in claim 13."],"number":15,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}